AMGN · Earnings call · 2026Q3T · Full report
Repatha Market Demand
AMGEN INC · 2026-11-03 · Importance 58 · Surprise 56 · No source text
Repatha sales grew 37% year-over-year to $1.1 billion, and U.S. average weekly new-to-brand prescriptions increased more than 60% year-over-year. Management cited greater treatment urgency in secondary prevention and high-risk primary prevention, with increasing adoption among cardiologists and primary-care physicians. The company expects more than 3 million additional patients globally to start treatment this year and estimates that 100 million patients worldwide remain above LDL-C goals.
Key facts
- Repatha generated $1.1 billion in Q3 2026 sales, up 37% year-over-year.
- U.S. average weekly new-to-brand prescriptions for Repatha increased over 60% versus the prior year.
- Amgen expects more than 3 million additional patients globally to start Repatha treatment in 2026.
- Amgen estimated that 100 million patients worldwide remain above their LDL-C goals.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +3.0% | Repatha generated $1.1 billion in Q3 2026 sales, up 37% year-over-year. |